CytomX Therapeutics, Inc. Stock Split Ratio
CytomX Therapeutics, Inc. (CTMX) reported Stock Split Ratio of 1.59% for the 0-month period ending 2015-10-02, per its 10-K filed 2017-03-02.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2017-03-02
- 2015-10-02: Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month 1.59%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month |
|---|---|
| 2015-10-02 | 1.59% 10-K · filed 2017-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |